Corpus Intelligence IC Memo — ST CHARLES HOSPITAL 2026-04-26 10:37 UTC
IC Memo — ST CHARLES HOSPITAL
Investment Committee Memorandum | NY | 167 beds | Grade C | EBITDA uplift $17.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST CHARLES HOSPITAL

CCN 330246 | SUFFOLK, NY | 167 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ST CHARLES HOSPITAL is a 167-bed suburban community hospital in SUFFOLK, NY with $233.4M in net patient revenue and a -6.5% operating margin. The hospital serves a payer mix of 24.1% Medicare, 3.7% Medicaid, and 72.1% commercial.

Thesis: Undervalued. Our ML models identify $17.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -6.5% to 0.9% (+736bps).

Net Revenue HCRIS$233.4M
Current EBITDA COMPUTED$-15.2M
Operating Margin COMPUTED-6.5%
Occupancy HCRIS69.1%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS25.5%
Distress Probability ML42.9%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
96
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -6.5% places it above the state median. Among 96 size-comparable peers (84-334 beds), the median margin is -17.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (84-334), prioritizing same-state peers. 96 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST CHARLES HOSPITAL (Target)NY167$233.4M-6.5%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
WHITE PLAINS HOSPITALNY292$884.7M8.7%
ROSWELL PARK CANCER INSTITUTENY142$772.3M-40.1%
SOUTH SHORE UNIVERSITY HOSPITANY312$700.5M-38.5%
LINCOLN MEDICAL&MENTAL HEALTH NY287$693.5M-22.9%
QUEENS HOSPITAL CENTERNY200$637.2M4.9%
JAMAICA HOSPITAL MEDICAL CENTENY280$610.4M-18.6%
SOUTH NASSAU COMMUNITIES HOSPINY312$594.1M-19.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $17.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$4.9M+210bp18mo
Cost to Collect4.5%2.5%$4.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.8M+122bp9mo
Clean Claim Rate88.0%96.0%$149K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$4.9M
Cost to Collect
$4.7M
Denial Rate Reduction
$4.6M
A/R Days Reduction
$2.8M
Clean Claim Rate
$149K
Total EBITDA Uplift$17.2M
Current EBITDA$-15.2M
+ RCM Uplift+$17.2M
Pro Forma EBITDA$2.0M
Current Margin-6.5%
Pro Forma Margin0.9%
WC Released (1x)$9.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-23.3M$71.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-23.3M$71.4M0.00x-100.0%
Bull Case9.0x11.0x$-21.0M$120.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-21.0M$125.3M0.00x-100.0%
Bear Case11.0x10.0x$-25.7M$-6.5M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-25.7M$-15.5M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 96 hospitals with 84-334 beds
  • Same-state prioritization (n=97)
  • Comp margins: P25=-27.6% / P50=-17.4% / P75=-9.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.